Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venixxa for Post-Thrombotic Syndrome
NCT03833024Phase 3Unknown
- Sponsor
- Jewish General Hospital
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of micronized purified flavonoid fraction in post-thrombotic syndrome (PTS), sponsored by Jewish General Hospital. Primary endpoint: Change in Post-Thrombotic Syndrome at 6 months. Status: unknown.
02
Drugs
micronized purified flavonoid fraction
03
Conditions
post-thrombotic syndrome (PTS)
Beyond the preview
Go deeper on NCT03833024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833024.